ASO作者反思：优化可切除胰腺癌的治疗：CA19-9>500 U/mL作为新辅助治疗的生物学指标 - Suppr | 超能文献

相似文献

1

ASO Author Reflections: Optimizing Treatment for Resectable Pancreatic Cancer: CA19-9 > 500 U/mL as a Biologic Indicator for Neoadjuvant Therapy.ASO作者反思：优化可切除胰腺癌的治疗：CA19-9>500 U/mL作为新辅助治疗的生物学指标

Ann Surg Oncol. 2025 May 21. doi: 10.1245/s10434-025-17458-8.

2

Resectable Pancreatic Cancer with CA19-9 > 500 U/mL: A Biological Indicator for Survival Benefit with Intensive Neoadjuvant Chemotherapy.CA19-9大于500 U/mL的可切除胰腺癌：强化新辅助化疗生存获益的生物学指标

Ann Surg Oncol. 2025 May 13. doi: 10.1245/s10434-025-17407-5.

3

ASO Visual Abstract: Resectable Pancreatic Cancer with CA19-9 > 500 U/mL-A Biological Indicator for Survival Benefit with Intensive Neoadjuvant Chemotherapy.ASO可视化摘要：CA19-9>500 U/mL的可切除胰腺癌——强化新辅助化疗生存获益的生物学指标

Ann Surg Oncol. 2025 Aug;32(8):5442-5443. doi: 10.1245/s10434-025-17562-9.

4

Prognostic Significance of Post-Neoadjuvant Chemotherapy Carbohydrate Antigen 19-9 Levels in Patients With Resectable Pancreatic Cancer Treated With S-1 and Gemcitabine: A Retrospective Cohort Study.S-1与吉西他滨治疗的可切除胰腺癌患者新辅助化疗后糖类抗原19-9水平的预后意义：一项回顾性队列研究

World J Oncol. 2025 Jun;16(3):269-275. doi: 10.14740/wjon2563. Epub 2025 Jun 14.

5

Prognostic impact of post-neoadjuvant CA19-9 values in pancreatic cancer: more pronounced following neoadjuvant chemotherapy compared to neoadjuvant chemoradiotherapy.新辅助治疗后CA19-9值对胰腺癌预后的影响：与新辅助放化疗相比，新辅助化疗后的影响更为显著。

Pancreatology. 2025 Jun 28. doi: 10.1016/j.pan.2025.06.016.

6

Comparison of neoadjuvant treatment and surgery first for resectable or borderline resectable pancreatic carcinoma: A systematic review and network meta-analysis of randomized controlled trials.新辅助治疗与手术优先治疗可切除或交界可切除胰腺癌的比较：一项随机对照试验的系统评价和网络荟萃分析。

PLoS One. 2024 Mar 7;19(3):e0295983. doi: 10.1371/journal.pone.0295983. eCollection 2024.

7

ASO Author Reflections: Carcinoembryonic Antigen as a Predictor of Failure to Reach Surgery in Patients with Borderline Resectable Pancreatic Cancer Undergoing Neoadjuvant Therapy.ASO作者反思：癌胚抗原作为新辅助治疗的临界可切除胰腺癌患者无法进行手术的预测指标

Ann Surg Oncol. 2025 May 28. doi: 10.1245/s10434-025-17536-x.

8

Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages.胰腺癌的术前/新辅助治疗：反应和切除率的系统评价和荟萃分析。

PLoS Med. 2010 Apr 20;7(4):e1000267. doi: 10.1371/journal.pmed.1000267.

9

Predictive value of baseline serum carbohydrate antigen 19-9 level on treatment effect of neoadjuvant chemoradiotherapy in patients with resectable and borderline resectable pancreatic cancer in two randomized trials.在两项随机试验中，基线血清碳水化合物抗原 19-9 水平对可切除和交界可切除胰腺癌患者新辅助放化疗治疗效果的预测价值。

Br J Surg. 2023 Sep 6;110(10):1374-1380. doi: 10.1093/bjs/znad210.

10

Comparing upfront surgery with neoadjuvant treatments in patients with resectable, borderline resectable or locally advanced pancreatic cancer: a systematic review and network meta-analysis of randomized clinical trials.比较可切除、边界可切除或局部进展期胰腺癌患者的 upfront 手术与新辅助治疗：随机临床试验的系统评价和网络荟萃分析。

Int J Surg. 2024 Jun 1;110(6):3900-3909. doi: 10.1097/JS9.0000000000001313.

引用本文的文献

1

ASO Author Reflections: A New Proposal for Therapeutic Strategies in Patients with High-Grade Pancreatic Intraepithelial Neoplasia at the Pancreatic Transection Margin in Pancreatic Ductal Adenocarcinoma.ASO作者反思：针对胰腺导管腺癌胰腺横断缘高级别胰腺上皮内瘤变患者治疗策略的新建议。

Ann Surg Oncol. 2025 Aug;32(8):5432-5433. doi: 10.1245/s10434-025-17508-1. Epub 2025 May 28.

本文引用的文献

1

ASO Visual Abstract: Resectable Pancreatic Cancer with CA19-9 > 500 U/mL-A Biological Indicator for Survival Benefit with Intensive Neoadjuvant Chemotherapy.ASO可视化摘要：CA19-9>500 U/mL的可切除胰腺癌——强化新辅助化疗生存获益的生物学指标

Ann Surg Oncol. 2025 Aug;32(8):5442-5443. doi: 10.1245/s10434-025-17562-9.

2

Resectable Pancreatic Cancer with CA19-9 > 500 U/mL: A Biological Indicator for Survival Benefit with Intensive Neoadjuvant Chemotherapy.CA19-9大于500 U/mL的可切除胰腺癌：强化新辅助化疗生存获益的生物学指标

Ann Surg Oncol. 2025 May 13. doi: 10.1245/s10434-025-17407-5.

3

Serum DUPAN-2 could be an Alternative Biological Marker for CA19-9 Nonsecretors with Pancreatic Cancer.